文献速递免疫规划卫生政策与健康促进

塞内加尔单年龄组常规免疫规划人乳头瘤病毒疫苗接种项目的成本

Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal.
PubMed 文献 · Vaccine · 2021-12-23

2018年塞内加尔将人乳头瘤病毒(HPV)疫苗纳入全国9岁女童常规免疫规划,本研究从提供方视角回顾性评估其增量成本。不含疫苗项目活动成本时,财务与经济交付成本分别为1,152,351美元和2,838,466美元(每剂分别为3.07美元和7.56美元),共接种375,608剂;含疫苗项目活动成本(每剂4.68美元)后财务总成本为2,911,343美元(每剂7.75美元)。

要点

  • 不含疫苗项目活动成本的财务与经济交付成本分别为每剂3.07美元和7.56美元。
  • 含疫苗项目活动成本(每剂4.68美元)后,财务总成本为每剂7.75美元。
  • 培训与每日津贴占财务成本最大份额,服务提供与人员时间占经济成本最大份额。

核心结论

  • 该成本评估可支持塞内加尔未来的疫苗引入,并为计划全国引入HPV疫苗的其他国家提供参考。
  • 研究结果支持既往成本研究关于从HPV疫苗试点示范项目过渡到全国引入时可能存在规模经济的预期。

研究设计与样本

  • 研究为回顾性、增量、基于投入物的成本评估,采用提供方视角。
  • 研究时段从2018年塞内加尔首次规划会议至2020年初数据收集。
  • 成本数据从国家和区域两级所有相关单位收集。
  • 采用多阶段整群抽样获得地区与卫生机构的国家代表性样本,并对样本单位成本加权以估算全部单位成本。
  • 成本评估基于四个维度:项目活动、资源投入、支付方和行政层级。

主要发现

  • 不含疫苗项目活动成本时,财务交付成本为1,152,351美元,经济交付成本为2,838,466美元(每剂分别为3.07美元和7.56美元)。
  • 含疫苗项目活动成本(每剂4.68美元)时,财务总成本为2,911,343美元(每剂7.75美元)。
  • 培训与每日津贴占财务成本最大份额。
  • 服务提供与人员时间占经济成本最大份额。
  • 按行政层级,地区级和卫生机构级分别占财务成本和经济成本最大份额。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: In 2018, Senegal introduced human papillomavirus (HPV) vaccine into its routine immunization program for all nine-year-old girls nationwide. We evaluated the costs of Senegal's introduction of HPV vaccine via this delivery approach. METHODS: We conducted a retrospective, incremental, ingredients-based cost evaluation from the provider perspective. The study timeframe included Senegal's first planning meeting in 2018 through data collection in early 2020. We collected costs from all involved units at the national and regional levels. A multi-stage cluster sampling approach was used to obtain a nationally representative sample of districts and health facilities. Weights were applied to costs from sampled units to estimate costs across all units. The cost evaluation was based on four dimensions: program activity, resource input, payer, and administrative level. Total costs were divided by the number of HPV doses administered to determine cost per dose and per dimension. RESULTS: Excluding vaccine program activity costs, the total financial and economic delivery costs of Senegal's HPV vaccination program were US$ 1,152,351 and US$ 2,838,466, respectively (US$ 3.07 and US$ 7.56 per dose, respectively). A total of 375,608 HPV vaccine doses were administered during the cost evaluation. Training and per diem represented the largest shares of financial costs. Service delivery and personnel time accounted for the largest shares of economic costs. By administrative level, district and health facility levels had the largest shares of financial and economic costs, respectively. Senegal's Ministry of Health accounted for the largest share of financial and economic costs. Including vaccine program activity costs (US$ 4.68/per dose), the total financial cost was US$ 2,911,343 (US$ 7.75 per dose). CONCLUSION: This cost evaluation can support Senegal's future vaccine introductions and inform other countries planning to introduce HPV vaccine nationwide. These findings support previous costing studies which anticipated potential economies of scale during the transition from HPV vaccine pilot demonstration projects to national introduction.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Brennan T, Hidle A, Doshi RH, et al. Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal. Vaccine. 2021. PMID: 34955325. doi:10.1016/j.vaccine.2021.11.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。